In a report released today, Doug Schenkel from Cowen & Co. reiterated a Buy rating on Danaher Corp (NYSE: DHR), with a price target of $120. The company’s shares opened today at $109.55, close to its 52-week high of $109.93.
According to TipRanks.com, Schenkel is a top 100 analyst with an average return of 27.3% and a 73.9% success rate. Schenkel covers the Healthcare sector, focusing on stocks such as Becton Dickinson, Myriad Genetics, and NanoString Tech.
Danaher Corp has an analyst consensus of Moderate Buy, with a price target consensus of $115.67.
See today’s analyst top recommended stocks >>
Danaher Corp’s market cap is currently $76.24B and has a P/E ratio of 28.90. The company has a Price to Book ratio of 2.80.
Based on the recent corporate insider activity of 76 insiders, corporate insider sentiment is negative on the stock. Most recently, in August 2018, William Daniel, the EVP of DHR sold 103,086 shares for a total of $10,373,440.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Danaher Corp. operates as a medical company, which designs, manufactures, and markets healthcare, environmental, and industrial equipment. It operates through the following segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
